We previously demonstrated that FASN inhibitors such as C75 operate as bona fide anti-estrogens, likely by alleviating AKT cross-inhibition of ERK and feeding signaling loops that boost a non-genomic ERα/MAPK cross-talk capable of transactivate ERα-driven tumor suppressive responses [36]. This evidence concerns the gene MAPK1 and neoplasm.